Participants in the study will receive either clarithromycin or azithromycin over a period of time, and their progress will be monitored to see how well the bacteria in their lungs respond to the treatment. The main goal is to see if the bacteria are cleared from the lungs after six months of treatment. The study will also look at other factors, such as any side effects from the medications and improvements in lung health as seen on scans.

Throughout the study, participants will have regular check-ups to monitor their health and the effectiveness of the treatment. This includes checking for any digestive issues or liver problems, as well as assessing overall health improvements. The study aims to provide more options for doctors in choosing the best treatment for patients with Mycobacterium avium complex lung infections.